State of Alaska Department of Revenue Has $377,000 Stock Position in LivaNova PLC (NASDAQ:LIVN)

State of Alaska Department of Revenue trimmed its holdings in shares of LivaNova PLC (NASDAQ:LIVNGet Rating) by 3.1% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 7,431 shares of the company’s stock after selling 235 shares during the period. State of Alaska Department of Revenue’s holdings in LivaNova were worth $377,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently bought and sold shares of the company. Loomis Sayles & Co. L P raised its position in LivaNova by 601.5% during the second quarter. Loomis Sayles & Co. L P now owns 601,679 shares of the company’s stock valued at $37,587,000 after buying an additional 515,914 shares during the period. Clearline Capital LP acquired a new position in LivaNova during the second quarter valued at $438,000. Mirae Asset Global Investments Co. Ltd. acquired a new position in LivaNova during the second quarter valued at $1,120,000. Duality Advisers LP raised its position in LivaNova by 496.0% during the second quarter. Duality Advisers LP now owns 22,178 shares of the company’s stock valued at $1,385,000 after buying an additional 18,457 shares during the period. Finally, Perpetual Investment Management Ltd increased its position in LivaNova by 7.3% in the 2nd quarter. Perpetual Investment Management Ltd now owns 100,971 shares of the company’s stock worth $6,308,000 after purchasing an additional 6,874 shares during the last quarter. 98.89% of the stock is owned by institutional investors and hedge funds.

LivaNova Stock Performance

LIVN opened at $57.67 on Friday. The company has a market cap of $3.09 billion, a PE ratio of -32.95 and a beta of 0.84. The stock has a 50-day moving average of $54.06 and a 200-day moving average of $55.47. LivaNova PLC has a 52-week low of $41.82 and a 52-week high of $88.00. The company has a debt-to-equity ratio of 0.45, a quick ratio of 2.53 and a current ratio of 2.96.

LivaNova (NASDAQ:LIVNGet Rating) last announced its earnings results on Wednesday, November 2nd. The company reported $0.58 earnings per share for the quarter, beating the consensus estimate of $0.57 by $0.01. LivaNova had a positive return on equity of 9.28% and a negative net margin of 9.14%. The firm had revenue of $252.60 million during the quarter, compared to the consensus estimate of $246.53 million. As a group, equities research analysts forecast that LivaNova PLC will post 1.73 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

LIVN has been the topic of several research reports. Barclays initiated coverage on LivaNova in a research report on Wednesday, December 21st. They issued an “equal weight” rating and a $62.00 target price on the stock. Piper Sandler dropped their target price on LivaNova from $94.00 to $84.00 in a research report on Wednesday, November 2nd. StockNews.com raised LivaNova from a “hold” rating to a “buy” rating in a research report on Monday, December 19th. TheStreet lowered LivaNova from a “c-” rating to a “d” rating in a research report on Wednesday, October 19th. Finally, Needham & Company LLC dropped their target price on LivaNova from $88.00 to $77.00 and set a “buy” rating on the stock in a research report on Wednesday, November 2nd. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, LivaNova has a consensus rating of “Moderate Buy” and a consensus price target of $79.50.

Insider Activity at LivaNova

In related news, CEO Damien Mcdonald sold 2,220 shares of the stock in a transaction that occurred on Thursday, December 15th. The stock was sold at an average price of $54.56, for a total transaction of $121,123.20. Following the completion of the sale, the chief executive officer now owns 83,749 shares in the company, valued at approximately $4,569,345.44. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 0.38% of the stock is owned by corporate insiders.

LivaNova Profile

(Get Rating)

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.

Featured Stories

Institutional Ownership by Quarter for LivaNova (NASDAQ:LIVN)

Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.